Next Article 
Antimicrobial Agents and Chemotherapy, June 2003, p. 1777-1783, Vol. 47, No. 6
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.6.1777-1783.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study
D. J. Farrell,1* S. Douthwaite,2 I. Morrissey,1 S. Bakker,1 J. Poehlsgaard,2 L. Jakobsen,2 and D. Felmingham1
GR Micro Limited, London, United Kingdom,1
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark2
Received 20 November 2002/
Returned for modification 25 January 2003/
Accepted 16 March 2003
Sixteen (1.5%) of the 1,043 clinical macrolide-resistant Streptococcus pneumoniae isolates collected and analyzed in the 1999-2000 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study have resistance mechanisms other than rRNA methylation or efflux. We have determined the macrolide resistance mechanisms in all 16 isolates by sequencing the L4 and L22 riboprotein genes, plus relevant segments of the four genes for 23S rRNA, and the expression of mutant rRNAs was analyzed by primer extension. Isolates from Canada (n = 4), Japan (n = 3), and Australia (n = 1) were found to have an A2059G mutation in all four 23S rRNA alleles. The Japanese isolates additionally had a G95D mutation in riboprotein L22; all of these originated from the same collection center and were clonal. Three of the Canadian isolates were also clonal; the rest were not genetically related. Four German isolates had A2059G in one, two, and three 23S rRNA alleles and A2058G in two 23S rRNA alleles, respectively. An isolate from the United States had C2611G in three 23S rRNA alleles, one isolate from Poland had A2058G in three 23S rRNA alleles, one isolate from Turkey had A2058G in four 23S rRNA alleles, and one isolate from Canada had A2059G in two 23S rRNA alleles. Erythromycin and clindamycin resistance gradually increased with the number of A2059G alleles, whereas going from one to two mutant alleles caused sharp rises in the azithromycin, roxithromycin, and rokitamycin MICs. Comparisons of mutation dosage with rRNA expression indicates that not all alleles are equally expressed. Despite their high levels of macrolide resistance, all 16 isolates remained susceptible to the ketolide telithromycin (MICs, 0.015 to 0.25 µg/ml).
* Corresponding author. Mailing address: GR Micro Limited, 7-9 William Rd., London NW1 3ER, United Kingdom. Phone: 44 (0)20 73887320. Fax: 44 (0)20 73887324. E-mail:
D.Farrell{at}grmicro.co.uk.
Antimicrobial Agents and Chemotherapy, June 2003, p. 1777-1783, Vol. 47, No. 6
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.6.1777-1783.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Wolter, N., Smith, A. M., Farrell, D. J., Northwood, J. B., Douthwaite, S., Klugman, K. P.
(2008). Telithromycin Resistance in Streptococcus pneumoniae Is Conferred by a Deletion in the Leader Sequence of erm(B) That Increases rRNA Methylation. Antimicrob. Agents Chemother.
52: 435-440
[Abstract]
[Full Text]
-
Wolter, N., Smith, A. M., Low, D. E., Klugman, K. P.
(2007). High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae. Antimicrob. Agents Chemother.
51: 1092-1095
[Abstract]
[Full Text]
-
Biswas, S., Raoult, D., Rolain, J.-M.
(2006). Molecular Characterization of Resistance to Macrolides in Bartonella henselae.. Antimicrob. Agents Chemother.
50: 3192-3193
[Abstract]
[Full Text]
-
Gygax, S. E., Schuyler, J. A., Kimmel, L. E., Trama, J. P., Mordechai, E., Adelson, M. E.
(2006). Erythromycin and clindamycin resistance in group B streptococcal clinical isolates.. Antimicrob. Agents Chemother.
50: 1875-1877
[Abstract]
[Full Text]
-
Farrell, D. J., Shackcloth, J., Barbadora, K. A., Green, M. D.
(2006). Streptococcus pyogenes Isolates with High-Level Macrolide Resistance and Reduced Susceptibility to Telithromycin Associated with 23S rRNA Mutations. Antimicrob. Agents Chemother.
50: 817-818
[Abstract]
[Full Text]
-
Wolter, N., Smith, A. M., Farrell, D. J., Klugman, K. P.
(2006). Heterogeneous Macrolide Resistance and Gene Conversion in the Pneumococcus. Antimicrob. Agents Chemother.
50: 359-361
[Abstract]
[Full Text]
-
Yassin, A., Fredrick, K., Mankin, A. S.
(2005). Deleterious mutations in small subunit ribosomal RNA identify functional sites and potential targets for antibiotics. Proc. Natl. Acad. Sci. USA
102: 16620-16625
[Abstract]
[Full Text]
-
Kasbekar, N., Acharya, P. S.
(2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm
62: 905-916
[Abstract]
[Full Text]
-
Pfister, P., Corti, N., Hobbie, S., Bruell, C., Zarivach, R., Yonath, A., Bottger, E. C.
(2005). 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A->G. Proc. Natl. Acad. Sci. USA
102: 5180-5185
[Abstract]
[Full Text]
-
Monaco, M., Camilli, R., D'Ambrosio, F., Del Grosso, M., Pantosti, A.
(2005). Evolution of erythromycin resistance in Streptococcus pneumoniae in Italy. J Antimicrob Chemother
55: 256-259
[Abstract]
[Full Text]
-
Reinert, R. R.
(2004). Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother
53: 918-927
[Abstract]
[Full Text]